Mersana Therapeutics Overview

  • Founded
  • 2001

Founded
  • Status
  • Public

  • Employees
  • 169

Employees
  • Stock Symbol
  • MRSN

Stock Symbol
  • Share Price
  • $7.45

  • (As of Thursday Closing)

Mersana Therapeutics General Information

Description

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Contact Information

Website
www.mersana.com
Formerly Known As
Nanopharma, Nanopharma Corporation
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 840 Memorial Drive
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Mersana Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mersana Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.45 $7.82 $2.68 - $14.80 $760M 97.2M 1.53M -$2.44

Mersana Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 255,716 274,803 1,568,610 155,855
Revenue 6,342 43 828 42,123
EBITDA (190,866) (168,003) (87,100) (28,955)
Net Income (193,931) (170,060) (88,045) (28,208)
Total Assets 252,351 206,111 273,399 107,541
Total Debt 37,427 38,176 16,572 7,764
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mersana Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mersana Therapeutics‘s full profile, request access.

Request a free trial

Mersana Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Mersana Therapeutics‘s full profile, request access.

Request a free trial

Mersana Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC plat
Biotechnology
Cambridge, MA
169 As of 2021
00000
000000000 00000

000000

rem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
0000000000000
Beijing, China
000 As of 0000
00000
0000000 0000 00000

000000

a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea c
0000 000000000
Boston, MA
0 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mersana Therapeutics Competitors (62)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mabworks Biotech Private Equity-Backed Beijing, China 000 00000 0000000 0000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
00000000 Private Equity-Backed San Carlos, CA 00 00000 000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
You’re viewing 5 of 62 competitors. Get the full list »

Mersana Therapeutics Patents

Mersana Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210220477-A1 Site specific antibody-drug conjugates with peptide-containing linkers Pending 09-Jan-2020 000000000
US-11155567-B2 Sting agonist compounds and methods of use Active 02-Aug-2019 0000000000 00
US-20210032269-A1 Sting agonist compounds and methods of use Granted 02-Aug-2019 0000000000
EP-3717021-A1 Pyrrolobenzodiazepine antibody conjugates Pending 27-Nov-2017 00000000000
JP-2020525441-A Drug-bearing polymer scaffolds and methods of making protein-polymer-drug conjugates Pending 22-Jun-2017 A61K38/08
To view Mersana Therapeutics’s complete patent history, request access »

Mersana Therapeutics Executive Team (23)

Name Title Board Seat Contact Info
Anna Protopapas Chief Executive Officer, President & Board Member
Brian DeSchuytner Senior Vice President of Finance and Product Strategy
Timothy Lowinger Ph.D Chief Scientific Officer & Chief Technology Officer, Technology
Ashish Mandelia Chief Accounting Officer, Accounting & Controller, Finance
Carla Poulson Chief Human Resources Officer & Chief People Officer
You’re viewing 5 of 23 executive team members. Get the full list »

Mersana Therapeutics Board Members (20)

Name Representing Role Since
Allene Diaz Mersana Therapeutics Board Member 000 0000
Andrew Hack Ph.D Self Board Member 000 0000
Anna Protopapas Mersana Therapeutics Chief Executive Officer, President & Board Member 000 0000
David Mott Self Chairman 000 0000
Kristen Hege MD Self Board Member 000 0000
You’re viewing 5 of 20 board members. Get the full list »

Mersana Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mersana Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Mersana Therapeutics‘s full profile, request access.

Request a free trial